Companies › Idera Pharmaceuticals
1 active drug program in 2 registered trials: 2 Phase 2; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tilsotolimod Toll-like receptor 9 agonist | TLR9 | Phase 2 | Solid Tumor; Malignant Melanoma | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03865082 | Tilsotolimod | Phase 2 | Solid Tumor | Oncology | Mar 2022 |
| NCT04126876 | Tilsotolimod | Phase 2 | Malignant Melanoma | Oncology | Nov 2031 |
Vasgene Therapeutics Suzhou BlueHorse Therapeutics Pieris Pharmaceuticals Evaxion Biotech Primmune Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.